Table 2.
Median Proportions of Adaptive Lymphocytesa Among 194 Study Participants, According to Polyomavirus Seropositivity, New Hampshire, 1993–1995b
| PyV Type and Serostatus |
Total |
Median Proportion (IQR) of Adaptive Lymphocytes |
|||
|---|---|---|---|---|---|
| No. | %c | CD8+ T Cells | CD4+ T Cells | B Cells | |
| BK | |||||
| Seropositive | 164 | 84.5 | 0.15 (0.11–0.18)d | 0.13 (0.10–0.17) | 0.03 (0.02–0.04)d |
| Seronegative | 30 | 15.5 | 0.17 (0.13–0.21) | 0.14 (0.10–0.16) | 0.02 (0.00–0.03) |
| JC | |||||
| Seropositive | 105 | 54.1 | 0.15 (0.12–0.19) | 0.13 (0.11–0.17) | 0.02 (0.01–0.04)d |
| Seronegative | 89 | 45.9 | 0.15 (0.12–0.18) | 0.12 (0.10–0.16) | 0.03 (0.02–0.04) |
| KI | |||||
| Seropositive | 177 | 91.2 | 0.15 (0.12–0.18) | 0.13 (0.10–0.17) | 0.03 (0.01–0.04) |
| Seronegative | 17 | 8.8 | 0.13 (0.11–0.15) | 0.15 (0.12–0.17) | 0.03 (0.01–0.05) |
| MCV | |||||
| Seropositive | 130 | 67.0 | 0.14 (0.11–0.18) | 0.13 (0.10–0.17) | 0.03 (0.01–0.04) |
| Seronegative | 64 | 33.0 | 0.16 (0.12–0.18) | 0.13 (0.10–0.15) | 0.03 (0.01–0.05) |
| HPyV6 | |||||
| Seropositive | 144 | 74.2 | 0.15 (0.12–0.18) | 0.13 (0.11–0.17) | 0.03 (0.01–0.04) |
| Seronegative | 50 | 25.8 | 0.14 (0.10–0.18) | 0.12 (0.09–0.14) | 0.03 (0.01–0.04) |
| HPyV7 | |||||
| Seropositive | 120 | 61.8 | 0.15 (0.12–0.18) | 0.13 (0.10–0.16) | 0.02 (0.01–0.04) |
| Seronegative | 74 | 38.1 | 0.14 (0.12–0.20) | 0.13 (0.10–0.18) | 0.03 (0.01–0.05) |
| TSV | |||||
| Seropositive | 163 | 84.0 | 0.15 (0.12–0.19) | 0.13 (0.10–0.17) | 0.02 (0.01–0.04) |
| Seronegative | 31 | 16.0 | 0.14 (0.12–0.16) | 0.13 (0.10–0.17) | 0.03 (0.01–0.04) |
| HPyV9 | |||||
| Seropositive | 38 | 19.6 | 0.13 (0.12–0.16)d | 0.13 (0.11–0.16) | 0.02 (0.01–0.03) |
| Seronegative | 156 | 80.4 | 0.15 (0.12–0.19) | 0.13 (0.10–0.17) | 0.03 (0.01–0.04) |
Abbreviations: IQR, interquartile range; PyV, polyomavirus.
a Proportions of adaptive lymphocytes were determined using the Illumina Infinium HumanMethylation27 BeadChip array (Illumina Inc., San Diego, California) and an algorithm published by Houseman et al. (45).
b PyV infection was determined using seropositivity for the VP1 protein.
c Percentage of participants who were within each given stratum of PyV seroreactivity. Percentages may not sum to 100 because of rounding.
d P < 0.05 for difference in medians between groups, as determined by the Wilcoxon rank-sum test.